Legal & General Group’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Legal & General Group’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-27,556	Closed	-$2.96M	–	3591
2023 Q1	$2.96M	Buy	27,556 +17,407	+172%	+$2M	﹤0.01%	1692
2022 Q4	$1.12M	Buy	10,149 +4,079	+67%	+$265K	﹤0.01%	2127
2022 Q3	$358K	Buy	6,070 +457	+8%	+$20.9K	﹤0.01%	2430
2022 Q2	$158K	Buy	5,613 +389	+7%	+$11.3K	﹤0.01%	2718
2022 Q1	$197K	Sell	5,224 -873	-14%	-$34.5K	﹤0.01%	2672
2021 Q4	$241K	Buy	6,097 +5,146	+541%	+$161K	﹤0.01%	2645
2021 Q3	$23K	Buy	951 +49	+5%	+$1.16K	﹤0.01%	3236
2021 Q2	$22K	Buy	+902	New	+$20.1K	﹤0.01%	3272

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

Legal & General Group's RXDX Position: Q2 2023 in Review

Legal & General Group sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 27,556 shares — an estimated $2.96M sold.

Legal & General Group first reported a position in RXDX in Q2 2021 and held it in 8 quarters. The position peaked at $2.96M in Q1 2023. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

Legal & General Group reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Legal & General Group sold 27,556 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $2.96M.
Legal & General Group first reported a position in Prometheus Biosciences, Inc. Common Stock in Q2 2021 and held it in 8 quarters.
Legal & General Group's Prometheus Biosciences, Inc. Common Stock position peaked at $2.96M in Q1 2023.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on Legal & General Group's 13F filing for Q2 2023, filed 14 Aug 2023.